Previous 10 | Next 10 |
Thinly traded nano cap Mereo BioPharma Group plc (NASDAQ: MREO ) is up 19% premarket on modest volume in reaction to additional data from a Phase 2b clinical trial, ASTEROID , evaluating setrusumab (BPS-804) in adults with Type I, III or IV osteogenesis imperfecta , also known ...
Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Reaching Statistical Significance in High Dose Cohort Statistically Significant Increase in Trabec...
Gainers: Adaptimmune Therapeutics (NASDAQ: ADAP ) +242% . More news on: Adaptimmune Therapeutics plc, Aethlon Medical, Inc., BioCardia, Inc., Stocks on the move, Read more ...
Thinly traded nano cap Mereo BioPharma Group ( MREO +27.1% ) is up more than double normal volume, albeit on turnover of only 465K shares, on the heels of its out-licensing agreement with Oncologie for exclusive global rights to ovarian cancer candidate navicixizumab, one of two assets M...
Adaptimmune Therapeutics PLC (NASDAQ: ADAP ) +56% as SPEAR T-cell platform delivers initial responses in four solid tumors. More news on: Adaptimmune Therapeutics plc, Verona Pharma plc, Mereo BioPharma Group plc, Stocks on the move, Read more ...
Oncologie receives exclusive global license to develop and commercialize navicixizumab LONDON, and REDWOOD CITY, Calif., and BOSTON, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," and Oncologie, Inc. (“Oncologieȁ...
Losers: Leap Therapeutics (NASDAQ: LPTX ) +49% . More news on: Leap Therapeutics, Inc., Yuma Energy, Inc., Inpixon, Stocks on the move, Read more ...
Novan (NASDAQ: NOVN ) -73% on failed SB206 study. More news on: Novan, Inc., DPW Holdings, Inc., Landec Corporation, Stocks on the move, Read more ...
Gainers: Inpixon (NASDAQ: INPX ) +125% . More news on: Inpixon, Synthesis Energy Systems, Inc., Trillium Therapeutics Inc., Stocks on the move, Read more ...
Neovasc (NASDAQ: NVCN ) -23% on announcing direct offering. More news on: Neovasc Inc., DURECT Corporation, Mereo BioPharma Group plc, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mereo BioPharma Group Company Name:
MREO Stock Symbol:
NASDAQ Market:
2024-03-28 08:00:08 ET Gil Blum from Needham issued a price target of $6.00 for MREO on 2024-03-28 07:08:00. The adjusted price target was set to $6.00. At the time of the announcement, MREO was trading at $3. The overall price target consensus is at $4.00 with high pric...
Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively Partnering discussions for alvelestat progressing with plans to initiate Phase 3 with a partn...
Iochpe-Maxion S.A. ADR (IOCJY) is expected to report for quarter end 2023-12-31 The Alkaline Water Company Inc. (WTER) is expected to report for Q3 2024 Clover Leaf Capital Corp. (CLOE) is expected to report for Q4 2023 Silvergate Capital Corporation Class A (SICP) is expected to repo...